Table 1.
AB | - | - | - | + | + | + |
rapamycin | - | + | + | - | + | + |
PD98059 | - | - | + | - | - | + |
Number | n = 8 | n = 8 | n = 8 | n = 8 | n = 8 | n = 8 |
LVEDd (mm) | 3.69±0.12 | 3.72±0.24 | 3.56±0.18 | 5.12±0.13** | 4.16±0.21*$ | 5.02±0.62** |
LVEDs (mm) | 2.64±0.34 | 2.58±0.26 | 2.75±0.12 | 4.6±0.42** | 2.92±0.38$$ | 3.84±0.27* |
LVPWd (mm) | 0.89±0.08 | 0.91±0.14 | 0.87±0.08 | 1.23±0.11* | 0.95±0.45$ | 1.18±0.02* |
IVSTd (mm) | 0.87±0.05 | 0.88±0.14 | 0.85±0.05 | 1.12±0.31* | 0.96±0.06$ | 1.09±0.04* |
EF% | 53.6±4.8 | 50.9±6.3 | 54.2±4.9 | 35.62±2.5** | 47.8±3.9$$ | 39.24±3.1** |
AB, LVEDd, left ventricular end-diastolic dimension (diastolic); LVEDs, left ventricular end-systolic dimension (systolic); LVPWd, left ventricular posterior wall (diastolic); IVSTd, interventricular septum thickness (diastolic); EF, ejection fraction. Data was represented as mean ± SEM, n = 8.
P < 0.05,
P < 0.01 vs. no-treatment groups.
P < 0.05,
P < 0.01 vs. AB group.